The prevention of coronary heart disease in women

Karen L. Margolis, Kristine Ensrud, Maria Maldonado, Pamela Charney, Tom Clayton, Janet Rich-Edwards, Joann Manson, Charles Hennekens, Julie Buring

Research output: Contribution to journalLetterpeer-review

1 Scopus citations

Abstract

To the Editor: Lipid-lowering drugs are generally expensive and frequently have bothersome side effects. Although primary-prevention trials have shown that lipid-lowering therapy can reduce the incidence of coronary heart disease in middle-aged men, meta-analysis of these trials has shown no effect of this type of therapy on overall survival.1 Concern about serious adverse effects of lipid-lowering drugs has prompted some to urge caution in their use in healthy, asymptomatic people.2 Although the Journal's recent review of primary prevention of coronary heart disease in women (June 29 issue)3 does not directly advocate the use of lipid-lowering drugs in women, we.

Original languageEnglish (US)
Pages (from-to)1570-1572
Number of pages3
JournalNew England Journal of Medicine
Volume333
Issue number23
DOIs
StatePublished - Dec 7 1995
Externally publishedYes

Fingerprint Dive into the research topics of 'The prevention of coronary heart disease in women'. Together they form a unique fingerprint.

Cite this